Home » Stocks » Magenta Therapeutics

Magenta Therapeutics, Inc. (MGTA)

Stock Price: $7.97 USD 0.39 (5.15%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 314.69M
Revenue (ttm) n/a
Net Income (ttm) -81.95M
Shares Out 39.59M
EPS (ttm) -2.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $7.97
Previous Close $7.58
Change ($) 0.39
Change (%) 5.15%
Day's Open 8.34
Day's Range 7.78 - 8.37
Day's Volume 748,064
52-Week Range 5.76 - 16.19

More Stats

Market Cap 314.69M
Enterprise Value 182.50M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 39.59M
Float 18.55M
EPS (basic) -2.13
EPS (diluted) -2.13
FCF / Share -1.54
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.02M
Short Ratio 6.49
Short % of Float 4.90%
Beta 2.85
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.24
Revenue n/a
Operating Income -87.86M
Net Income -81.95M
Free Cash Flow -60.76M
Net Cash 132.19M
Net Cash / Share 3.35
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -37.60%
ROE -63.18%
ROIC -89.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 4
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$18.00*
(125.85% upside)
Low
15.0
Current: 7.97
High
22.0
Target: 18.00
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue----
Operating Income-82.97-59.96-35.73-9.27
Net Income-76.77-57.52-35.49-9.43
Shares Outstanding37.0118.391.860.15
Earnings Per Share-2.07-3.13-19.12-65.15
Operating Cash Flow-57.10-41.89-22.26-6.53
Capital Expenditures-3.06-7.66-2.20-0.14
Free Cash Flow-60.16-49.55-24.46-6.67
Cash & Equivalents14814451.574.54
Net Cash / Debt14814451.574.54
Assets16215754.4611.34
Liabilities20.3211.674.1420.22
Book Value141146-42.12-8.87
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Magenta Therapeutics, Inc.
Country United States
Employees 70
CEO Jason Gardner

Stock Information

Ticker Symbol MGTA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MGTA

Description

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. Thecompany is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. It has a has a research and clinical collaboration agreement with AVROBIO, Inc.to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.